120 related articles for article (PubMed ID: 24745065)
21. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
23. Bosentan.
Prakash A; Perry CM
Am J Cardiovasc Drugs; 2002; 2(5):335-43; discussion 343. PubMed ID: 14727963
[TBL] [Abstract][Full Text] [Related]
24. Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
van Giersbergen PL; Popescu G; Bodin F; Dingemanse J
J Clin Pharmacol; 2003 Jan; 43(1):15-22. PubMed ID: 12520623
[TBL] [Abstract][Full Text] [Related]
25. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions.
Fattinger K; Funk C; Pantze M; Weber C; Reichen J; Stieger B; Meier PJ
Clin Pharmacol Ther; 2001 Apr; 69(4):223-31. PubMed ID: 11309550
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of plasma endothelin-1 level after bosentan administration in pulmonary arterial hypertension.
Hiramoto Y; Shioyama W; Higuchi K; Arita Y; Kuroda T; Sakata Y; Nakaoka Y; Fujio Y; Yamauchi-Takihara K
J Cardiol; 2009 Jun; 53(3):374-80. PubMed ID: 19477379
[TBL] [Abstract][Full Text] [Related]
27. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD.
Liefeldt L; van Giersbergen PL; Dingemanse J; Rudolph B; Walde T; Budde K; Neumayer HH; Hocher B
Am J Kidney Dis; 2004 May; 43(5):923-6. PubMed ID: 15112184
[TBL] [Abstract][Full Text] [Related]
28. Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension.
Hughes R; Jais X; Suntharalingam J; Humbert M; Parent F; Simonneau G; Pepke-Zaba J
Expert Opin Pharmacother; 2006 Jun; 7(9):1133-8. PubMed ID: 16732700
[TBL] [Abstract][Full Text] [Related]
29. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Suleman N; Frost AE
Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
[TBL] [Abstract][Full Text] [Related]
30. Single dose pharmacokinetics of terbinafine in cats.
Wang A; Ding H; Liu Y; Gao Y; Zeng Z
J Feline Med Surg; 2012 Aug; 14(8):540-4. PubMed ID: 22403416
[TBL] [Abstract][Full Text] [Related]
31. Development of an SPE-LC-MS/MS method for simultaneous quantification of bosentan and its active metabolite hydroxybosentan in human plasma to support a bioequivalence study.
Parekh JM; Shah DK; Sanyal M; Yadav M; Shrivastav PS
J Pharm Biomed Anal; 2012 Nov; 70():462-70. PubMed ID: 22789899
[TBL] [Abstract][Full Text] [Related]
32. Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension.
Williamson DJ; Wallman LL; Jones R; Keogh AM; Scroope F; Penny R; Weber C; Macdonald PS
Circulation; 2000 Jul; 102(4):411-8. PubMed ID: 10908213
[TBL] [Abstract][Full Text] [Related]
33. Greater functional ETB receptor antagonism with bosentan than sitaxsentan in healthy men.
MacIntyre IM; Dhaun N; Lilitkarntakul P; Melville V; Goddard J; Webb DJ
Hypertension; 2010 Jun; 55(6):1406-11. PubMed ID: 20404221
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics of drugs for pediatric pulmonary hypertension.
Nakau K; Sugimoto M; Oka H; Kajihama A; Maeda J; Yamagishi H; Kamiyama N; Tasaki Y; Kajino H; Azuma H
Pediatr Int; 2016 Nov; 58(11):1112-1117. PubMed ID: 27038140
[TBL] [Abstract][Full Text] [Related]
35. Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.
Volz AK; Krause A; Haefeli WE; Dingemanse J; Lehr T
Clin Pharmacokinet; 2017 Dec; 56(12):1499-1511. PubMed ID: 28401480
[TBL] [Abstract][Full Text] [Related]
36. Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.
Hiramoto Y; Shioyama W; Kuroda T; Masaki M; Sugiyama S; Okamoto K; Hirota H; Fujio Y; Hori M; Yamauchi-Takihara K
Circ J; 2007 Mar; 71(3):367-9. PubMed ID: 17322637
[TBL] [Abstract][Full Text] [Related]
37. Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
Aypar E; Alehan D; Karagöz T; Aykan HH; Ertugrul İ
Cardiol Young; 2018 Apr; 28(4):542-547. PubMed ID: 29233198
[TBL] [Abstract][Full Text] [Related]
38. Effect of dual endothelin receptor blockade on ocular blood flow in patients with glaucoma and healthy subjects.
Resch H; Karl K; Weigert G; Wolzt M; Hommer A; Schmetterer L; Garhöfer G
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):358-63. PubMed ID: 18719081
[TBL] [Abstract][Full Text] [Related]
39. Tracleer (bosentan).
Scarpa WJ
J Clin Hypertens (Greenwich); 2002; 4(1):73. PubMed ID: 11821645
[No Abstract] [Full Text] [Related]
40. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension.
Halank M; Miehlke S; Hoeffken G; Schmeisser A; Schulze M; Strasser RH
Transplantation; 2004 Jun; 77(11):1775-6. PubMed ID: 15201684
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
